继mRNA RSV(呼吸道合胞病毒)疫苗向美国食品和药品监督管理局(FDA)申报临床后不久,艾美疫苗2月11日公告,其自主研发的mRNA带状疱疹疫苗已向中国药品监督管理局药品评审中心(CDE)申报临床。近一个月以来,艾美两个重磅大单品mRNA疫苗陆续取得积极进展。单就这两款重磅大单品的优势来看,临床前动物试验中,第三方检测单位的检测结果显示,艾美疫苗的mRNA带状疱疹疫苗,其特异性T细胞免疫、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.